G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?

Rasmus Sejersten Ripa; Jens Kastrup

doi:10.1016/j.exphem.2008.01.010

G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?

24 Citationer (Scopus)

Abstract

This review of adjunctive therapy with subcutaneous granulocyte-colony stimulating factor (G-CSF) to patients with acute myocardial infarction (AMI) focus on the cardioprotective effects and potential mechanisms of G-CSF and discuss the therapeutic potential of G-CSF. All clinical trials published in peer-reviewed journals identified through PubMed are discussed. G-CSF treatment seems to be safe, and initial unblinded trials in patients with AMI were encouraging. However, larger double-blind placebo-controlled trials have not been able to demonstrate improved myocardial recovery after G-CSF treatment. Current controversies in interpretation of the results include 1) importance of direct cardiac effect of G-CSF vs indirect through bone marrow stem and progenitor cell mobilization, 2) importance of timing of G-CSF therapy, 3) importance of G-CSF dose, and 4) importance of cell types mobilized from the bone-marrow. Cell-based therapies to improve cardiac function remain promising and further experimental and clinical studies are warranted to determine the future role of G-CSF.

Originalsprog	Engelsk
Tidsskrift	Experimental Hematology
Vol/bind	36
Udgave nummer	6
Sider (fra-til)	681-6
Antal sider	6
ISSN	0301-472X
DOI	https://doi.org/10.1016/j.exphem.2008.01.010
Status	Udgivet - jun. 2008
Udgivet eksternt	Ja

Adgang til dokumentet

10.1016/j.exphem.2008.01.010

Citationsformater

@article{4f3bf511543a4598a515920eaacddade,

title = "G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?",

abstract = "This review of adjunctive therapy with subcutaneous granulocyte-colony stimulating factor (G-CSF) to patients with acute myocardial infarction (AMI) focus on the cardioprotective effects and potential mechanisms of G-CSF and discuss the therapeutic potential of G-CSF. All clinical trials published in peer-reviewed journals identified through PubMed are discussed. G-CSF treatment seems to be safe, and initial unblinded trials in patients with AMI were encouraging. However, larger double-blind placebo-controlled trials have not been able to demonstrate improved myocardial recovery after G-CSF treatment. Current controversies in interpretation of the results include 1) importance of direct cardiac effect of G-CSF vs indirect through bone marrow stem and progenitor cell mobilization, 2) importance of timing of G-CSF therapy, 3) importance of G-CSF dose, and 4) importance of cell types mobilized from the bone-marrow. Cell-based therapies to improve cardiac function remain promising and further experimental and clinical studies are warranted to determine the future role of G-CSF.",

keywords = "Animals, Bone Marrow Transplantation, Cardiotonic Agents, Clinical Trials as Topic, Disease Models, Animal, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Humans, Myocardial Infarction, Treatment Outcome",

author = "Ripa, {Rasmus Sejersten} and Jens Kastrup",

year = "2008",

month = jun,

doi = "10.1016/j.exphem.2008.01.010",

language = "English",

volume = "36",

pages = "681--6",

journal = "Experimental Hematology",

issn = "0301-472X",